SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc.
February 14 2014 - 1:06PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (Nasdaq:
CADX) relating to the acquisition by Mallinckrodt plc (“MNK”).
Click here to learn more about the investigation
http://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html,
or call: 877-534-2590. There is no cost or obligation to you.
Cadence announced that the transaction is a Tender Offer, which
should close, unless extended, 20 days after commencement. Under
the terms of the transaction, Cadence shareholders will receive
only $14.00 in cash for each share of Cadence stock they own. The
investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of Cadence
for not acting in the Company’s shareholders' best interests in
connection with the sale process.
The transaction may undervalue the Company as it is below the
premium paid in comparable transactions and an analyst has set a
$15.00 per share price target on Cadence stock. In addition, the
Company has announced OFIRMEV has continued to gain market share
and posted year-over-year sales growth of more than 100% in each
quarter of 2013.
If you own shares of Cadence common stock and wish to discuss
the legal ramifications of the proposed transaction, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or
Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza,
Suite 602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, or by visiting
http://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html,
or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and case action lawsuits. The attorneys at Brodsky &
Smith have been appointed by numerous courts throughout the country
to serve as lead counsel in class actions and successfully
recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith,
Esquire877-LEGAL-90investorrelations@brodsky-smith.comhttp://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html
(MM) (NASDAQ:CADX)
Historical Stock Chart
From Sep 2024 to Oct 2024
(MM) (NASDAQ:CADX)
Historical Stock Chart
From Oct 2023 to Oct 2024